Eleonora Farina1, Jenny Capuccini1, Gabriella Macchia2, Luciana Caravatta3, Nam P Nguyen4, Silvia Cammelli1, Andrea Farioli5, Giuseppe Zanirato Rambaldi6, Savino Cilla7, Tigeneh Wondemagegnhu8, A F M Kamal Uddin9, Mostafà Aziz Sumon10, Domenico Genovesi3, Milly Buwenge1, Francesco Cellini11, Vincenzo Valentini11, Francesco Deodato12, Alessio G Morganti1. 1. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. 2. Radiotherapy Unit, Department of Oncology, Giovanni Paolo II Foundation, Catholic University of Sacred Heart, Campobasso, Italy radiationtherapy.ef@gmail.com. 3. Department of Radiation Oncology, SS. Annunziata Hospital, G. D'Annunzio University of Chieti, Chieti, Italy. 4. Department of Radiation Oncology, Howard University College of Medicine, Washington, DC, U.S.A. 5. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. 6. Radiology Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. 7. Medical Physics Unit, Giovanni Paolo II Foundation, Catholic University of Sacred Heart, Campobasso, Italy. 8. Department of Radiotherapy, Black Lion Hospital, Addis-Ababa, Ethiopia. 9. Department of Radiation Oncology, United Hospital Limited, Dhaka, Bangladesh. 10. Clinical Oncology, Kurmitola General Hospital, Dhaka, Bangladesh. 11. Department of Radiotherapy, A. Gemelli Hospital, Catholic University, Rome, Italy. 12. Radiotherapy Unit, Department of Oncology, Giovanni Paolo II Foundation, Catholic University of Sacred Heart, Campobasso, Italy.
Abstract
AIM: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. PATIENTS AND METHODS: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. RESULTS: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. CONCLUSION: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies. Copyright
AIM: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. PATIENTS AND METHODS: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. RESULTS: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. CONCLUSION: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies. Copyright
Authors: Eleonora Farina; Gabriella Macchia; Milly Buwenge; Giambattista Siepe; Alice Zamagni; Silvia Cammelli; Savino Cilla; Tigeneh Wondemagegnhu; Aynalem A Woldemariam; A F M Kamal Uddin; Mostafà Aziz Sumon; Francesco Cellini; Francesco Deodato; Alessio G Morganti Journal: Clin Exp Metastasis Date: 2018-10-08 Impact factor: 5.150
Authors: Alessio G Morganti; Gabriella Macchia; Francesco Cellini; Francesco Deodato; Alice Zamagni; Giambattista Siepe; Milly Buwenge Journal: Front Oncol Date: 2022-02-23 Impact factor: 6.244
Authors: Alexander Fabian; Justus Domschikowski; Anne Letsch; Claudia Schmalz; Sandra Freitag-Wolf; Juergen Dunst; David Krug Journal: JAMA Netw Open Date: 2022-09-01
Authors: Francesco Cellini; Rossella Di Franco; Stefania Manfrida; Valentina Borzillo; Ernesto Maranzano; Stefano Pergolizzi; Alessio Giuseppe Morganti; Vincenzo Fusco; Francesco Deodato; Mario Santarelli; Fabio Arcidiacono; Romina Rossi; Sara Reina; Anna Merlotti; Barbara Alicja Jereczek-Fossa; Angelo Tozzi; Giambattista Siepe; Alberto Cacciola; Elvio Russi; Maria Antonietta Gambacorta; Marta Scorsetti; Umberto Ricardi; Renzo Corvò; Vittorio Donato; Paolo Muto; Vincenzo Valentini Journal: Radiol Med Date: 2021-09-27 Impact factor: 3.469